

Coordinated Epistasis Reveals Pathway Architecture (and method considerations)

Jolien Rietkerk

Helmholtz Pioneer Campus, Cai lab
WCPCG 2023, Montréal, Canada


Disclosure

Nothing to disclose

Pathways leading to diseases





Unknown diagnosis Y




N = 100K	Status
40K	Controls
70K	Cases


We think Y is actually Alzheimers + Type 2 Diabetes



Type 2 Diabetes



If we were right




$$Y \sim \alpha_i PRS_i + \alpha_j PRS_j + \gamma_{i,j} PRS_i * PRS_j$$

$$\gamma_{i,j} < 0$$

What if Y is a psych disorder


Major Depressive Disorder




N = 100K	Status
40K	Controls
??K	?? Subtype A
??K	?? Subtype B




Melancholic



Early Onset



Hard to do this




Pathway 1 ← What should this even be?

Coordinated Epistasis for assessing pathway architecture




Coordinated Epistasis (CE)




- $P_1 \approx$ PRS pathway 1
- $P_2 \approx$ PRS pathway 1

- Pathway specific variants are distributed all across the genome

Chromosome as partitions



Chromosome as partitions









$$y \sim \alpha_i PRS_i + \alpha_j PRS_j + \gamma_{ij} PRS_i * PRS_j$$

$$i, j \in \{1..22\}, i \neq j$$

In total, 231 pairs of chromosomes


Gamma indicates pathway architecture



Assess MDD pathway architecture in UKB

MDD	LifetimeMDD (67K)
Subtypes	6 clinical subtypes (N=25-65K)
Symptoms	14 symptoms CIDI-SF(N=50-100K)

10-fold Cross Validation (CV)




Caveats in using cross-validation PRS




CV creates batch effects


I. Clumping and thresholding



II. GWAS on varying individuals



Mundlak method corrects batch effect




$$y \sim \alpha_1 PRS'_1 + \alpha_2 PRS'_2 + \mu_p + \gamma_{1,2} PRS'_1 * PRS'_2$$

μ_p = mean of means

$$PRS' = PRS - \mu_p$$


MDD analysis in UKB

MDD	LifetimeMDD (67K)
Subtypes	6 clinical subtypes (N=25-65K)
Symptoms	14 symptoms CIDI-SF(N=50-100K)



MDD analysis in UKB

MDD	LifetimeMDD (67K)
Subtypes	6 clinical subtypes (N=25-65K)
Symptoms	14 symptoms CIDI-SF(N=50-100K)




Wide-ranging implication for PRS analyses

- For all analyses using CV-based PRS, where PRS are used as “phenotypes” or “covariates”
- Eg.
 - Multi-PRS predictions
 - PRS x SNP interactions
 - PRS x PRS interactions


Applying CE to identify
heterogeneity
in MDD phenotypes




Different definitions or meta-analyses of MDD have different levels of heterogeneity



MTAG to improve effective sample size





MTAG to improve effective sample size



MDD phenotypes from MTAG

Phenotype	Number of input GWAS	Description
MTAG.FamilyHistory	3	severe depression in family members
MTAG.ALLDep+Envs	9	Shallow MDD phenotypes and environment variables




CE detects heterogeneity in pathways in MDD from MTAG

Phenotype	Number of input GWAS	Description
MTAG.FamilyHistory	3	severe depression in family members
MTAG.AllDep	5	Various shallow MDD phenotypes
MTAG.ALLDep+Envs	9	Shallow MDD phenotypes and environment variables
MTAG.Gppsy	1	Gppsy
MTAG.Envs	5	Related environment variables
MTAg.All	12	Shallow MDD phenotypes, environment variables, family history

CE detects heterogeneity in pathways in MDD from MTAG


Phenotype	Number of input GWAS
MTAG.FamilyHistory	3
MTAG.AllDep	5
MTAG.ALLDep+Envs	9
MTAG.Gppsy	1
MTAG.Envs	5
MTAg.All	12



Summary

- CE detects pathway architecture
- 10x CV in PRS creates batch effect (wide-ranging implications!)
- Mundlak approach correct for batch effect in CV
- CE can detect significant pathway heterogeneity in heterogenous MDD meta-analyses

Acknowledgements



biobank^{uk}

**HELMHOLTZ
MUNICH**



X: @JolienRietkerk
Website: rietkerk-research.com